Last updated: August 10, 2026
Tirzepatide has become Eli Lilly’s principal growth asset. Sales of Mounjaro and Zepbound reached approximately $16.5 billion in 2024, up from roughly $5.2 billion in 2023 before Zepbound’s full commercial launch. Demand is being driven by type 2 diabetes, obesity, strong weight-loss efficacy, expanding reimbursement, and rapid growth of obesity pharmacotherapy.
The commercial outlook remains strong through the late 2020s. The principal constraints are manufacturing capacity, payer utilization controls, supply normalization, gastrointestinal tolerability, competition from semaglutide products, and the eventual emergence of authorized generics or other tirzepatide-based products after key patent and regulatory barriers weaken.
How large is the tirzepatide market?
Tirzepatide is marketed by Eli Lilly under two U.S. brands:
| Brand |
Active ingredient |
Primary indication |
FDA approval |
| Mounjaro |
Tirzepatide |
Type 2 diabetes |
May 13, 2022 |
| Zepbound |
Tirzepatide |
Chronic weight management and obesity-related obstructive sleep apnea |
November 8, 2023 |
Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. Zepbound uses the same active ingredient but is approved under a separate obesity brand.
What were Mounjaro and Zepbound sales in 2024?
Eli Lilly reported the following annual revenue:
| Product |
2023 revenue |
2024 revenue |
Year-over-year change |
| Mounjaro |
Approximately $5.16 billion |
Approximately $11.54 billion |
Approximately 124% |
| Zepbound |
Approximately $175 million, primarily fourth quarter |
Approximately $4.93 billion |
Not comparable because of launch timing |
| Combined tirzepatide brands |
Approximately $5.34 billion |
Approximately $16.47 billion |
Approximately 208% |
Tirzepatide represented roughly 37% of Eli Lilly’s 2024 revenue of approximately $45.0 billion. Mounjaro and Zepbound were the company’s most important growth products by a wide margin.[1]
The combined figure understates demand because Lilly’s revenue is limited by production capacity, prescription approval requirements, payer restrictions, and the time needed to scale injection-device manufacturing.
What is the financial trajectory for tirzepatide?
Tirzepatide revenue is likely to remain on a steep upward path through the second half of the decade, although annual growth rates should moderate as the base expands.
What is the near-term revenue outlook?
Lilly guided to 2025 companywide revenue of approximately $58 billion to $61 billion, reflecting continued growth from Mounjaro and Zepbound, new indications, higher manufacturing capacity, and other pipeline products.[2] Tirzepatide is expected to account for a substantial portion of the increase.
A reasonable commercial framework is:
| Period |
Market position |
Main financial drivers |
| 2024 |
Established blockbuster |
Diabetes demand, Zepbound launch, supply expansion |
| 2025-2026 |
Rapid expansion |
Obesity reimbursement, higher doses, international launches, expanded manufacturing |
| 2027-2029 |
Large-scale franchise |
Broader payer coverage, oral and combination competition, indication expansion |
| 2030 onward |
Maturing franchise |
Patent challenges, price pressure, authorized generics, next-generation therapies |
Revenue growth will depend less on initial patient demand than on Lilly’s ability to produce sufficient doses and secure durable insurance coverage.
Which factors could limit tirzepatide revenue?
The main commercial risks are:
- Payer restrictions requiring prior authorization or documented failure of cheaper therapies.
- Exclusion of anti-obesity drugs from employer-sponsored plans.
- High discontinuation rates associated with gastrointestinal side effects, cost, or weight regain after stopping treatment.
- Competition from Novo Nordisk’s Wegovy and Ozempic franchises.
- Greater use of lower-priced compounded or unauthorized products during supply shortages.
- Future oral incretin products that reduce dependence on weekly injections.
- Price concessions to government and commercial payers as obesity treatment becomes a larger budget item.
Zepbound’s commercial performance is particularly sensitive to insurance coverage. Diabetes treatment generally has stronger reimbursement than obesity treatment, so the product mix between Mounjaro and Zepbound affects net pricing and patient access.
How does tirzepatide compare with semaglutide?
Tirzepatide competes primarily with semaglutide, marketed by Novo Nordisk as Ozempic, Rybelsus, and Wegovy.
| Attribute |
Tirzepatide |
Semaglutide |
| Primary mechanism |
GIP and GLP-1 receptor agonist |
GLP-1 receptor agonist |
| Diabetes brand |
Mounjaro |
Ozempic |
| Obesity brand |
Zepbound |
Wegovy |
| Administration |
Once-weekly injection |
Once-weekly injection for Ozempic and Wegovy; daily oral Rybelsus |
| Weight-loss profile |
Generally higher mean weight loss in head-to-head evidence |
Strong weight-loss efficacy |
| Commercial owner |
Eli Lilly |
Novo Nordisk |
| Main competitive advantage |
Higher efficacy in several comparative analyses and rapid dose escalation options |
Larger installed base and broad physician familiarity |
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without diabetes.[3] The result supports premium positioning but does not eliminate semaglutide’s advantages in brand awareness, established prescriber behavior, supply infrastructure, and cardiovascular outcomes data.
Novo Nordisk has an important cardiovascular label advantage for Wegovy, while Lilly has pursued additional indications for tirzepatide, including obstructive sleep apnea. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, expanding the addressable market beyond weight reduction alone.[4]
What patents protect tirzepatide?
The central U.S. composition-of-matter patent for tirzepatide is U.S. Patent No. 10,034,938, assigned to Eli Lilly. The patent covers peptide compounds, including tirzepatide, and has an estimated expiration date in July 2036, subject to patent-term adjustment and any applicable patent-term extension.[5]
What is the core tirzepatide patent estate?
| Protection category |
Representative protection |
Commercial relevance |
| Active pharmaceutical ingredient |
U.S. Patent No. 10,034,938 |
Primary barrier to conventional generic tirzepatide |
| Formulation and dosage forms |
Additional Lilly patent families and applications |
May affect injectable compositions, concentrations, and delivery formats |
| Treatment methods |
Patents covering diabetes, obesity, weight reduction, and related uses |
Relevant to ANDA labeling and skinny-label strategies |
| Device and presentation |
Pen, cartridge, container, and delivery-system rights |
Can delay device-substitutable products even after API patent expiry |
| Manufacturing and process know-how |
Lilly trade secrets and process patents |
Raises technical barriers to consistent peptide production |
The composition patent is the most important barrier because an ANDA applicant generally cannot market a conventional copy of tirzepatide while a valid, enforceable composition patent remains in force.
Public patent databases and FDA Orange Book records should be reviewed together. Orange Book listings control the formal patent-certification framework for approved drug products, while broader patent families can affect litigation, licensing, formulation substitution, and product design.[5][6]
What formulations are protected by tirzepatide patents?
Lilly’s commercial products use sterile, injectable tirzepatide formulations in single-dose pens and related presentations. Formulation-related protection can cover:
- Concentration and excipient combinations.
- pH and stability characteristics.
- Multi-dose or single-dose delivery formats.
- Cartridge and pen configurations.
- Storage and handling conditions.
- Specific manufacturing and fill-finish processes.
Formulation patents generally have less value than a composition patent if a competitor can develop a non-infringing formulation. Their commercial value increases when the FDA-approved reference product depends on a particular concentration, device, or presentation that is difficult to substitute.
When does tirzepatide lose exclusivity?
The most important U.S. date is the estimated July 2036 expiration of the core composition patent. FDA regulatory exclusivity is shorter.
What is the FDA exclusivity status of Mounjaro and Zepbound?
Mounjaro was approved in May 2022. As a new molecular entity, it received five-year new chemical entity exclusivity, subject to FDA regulatory treatment of the active moiety and any applicable pediatric provisions.[7]
Zepbound was approved in November 2023 for obesity. Its approval does not necessarily create a new five-year exclusivity period for tirzepatide because the active ingredient had already been approved in Mounjaro. The relevant exclusivity period depends on the regulatory classification of the supplemental indication and the clinical investigations supporting the approval.
The practical effect is that FDA regulatory exclusivity is expected to expire well before the core composition patent. Patent protection, not NCE exclusivity, is the principal barrier to generic entry.
What could extend tirzepatide exclusivity?
Potential extensions include:
- Patent-term adjustment based on USPTO examination delays.
- Patent-term extension for regulatory review under 35 U.S.C. §156, if statutory conditions are met.
- Pediatric exclusivity, if FDA-required pediatric studies qualify.
- Later-expiring patents covering formulations, devices, manufacturing, or new indications.
- Regulatory exclusivity for new clinical investigations supporting a distinct indication.
These mechanisms do not automatically extend all rights across all tirzepatide products. Their effect depends on the specific patent, indication, dosage form, and FDA listing.
What is the Orange Book status of tirzepatide?
Mounjaro and Zepbound are FDA-approved drug products subject to Orange Book patent-listing rules. The Orange Book is the key source for identifying patents that Lilly asserts against ANDA applicants for the approved products.[6]
A complete Orange Book review should distinguish:
- Patents that claim tirzepatide itself.
- Patents that claim an approved formulation.
- Patents that claim a method of use.
- Device or presentation patents.
- Patents that are listed for Mounjaro but not Zepbound, or vice versa.
- Expired, delisted, or withdrawn patent entries.
The Orange Book record can change through FDA updates, patent delistings, litigation outcomes, or corrections. A market-access assessment should therefore use the current FDA listing rather than relying on a static patent summary.
Which companies are challenging tirzepatide patents?
As of the available public record, generic competition has focused more visibly on unauthorized compounded products, telehealth distribution, and supply-related disputes than on a mature wave of commercial ANDA Paragraph IV litigation comparable to older small-molecule blockbusters.
Potential ANDA challengers would likely include large generic manufacturers with peptide capabilities, sterile injectable infrastructure, or partnerships with specialized contract manufacturers. A Paragraph IV filing could target:
- The core composition patent.
- Formulation patents.
- Method-of-use patents.
- Device patents.
- Later-expiring patents that affect the commercial presentation.
A generic applicant could seek a first-filer advantage by challenging a listed patent before its expiration. Lilly would normally have the ability to bring patent litigation within the statutory framework, potentially triggering a 30-month stay of FDA approval for the challenged ANDA, subject to applicable exceptions and court developments.[8]
What generic entry risks exist for tirzepatide?
What would a Paragraph IV challenge mean?
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. The applicant could also use a Paragraph III certification and wait for patent expiration, but a Paragraph IV route is more commercially aggressive.
The principal generic-entry scenarios are:
| Scenario |
Likely timing |
Commercial impact |
| No successful challenge |
Through core patent expiry |
Lilly retains broad control |
| Formulation-only challenge |
Before 2036 if non-infringing product is feasible |
Limited or delayed competition |
| Successful core patent challenge |
Potentially before 2036 |
Major price and share erosion |
| Authorized generic or Lilly license |
Before patent expiry |
Controlled price segmentation |
| Biosimilar-style competition |
Not applicable to tirzepatide |
Tirzepatide is a chemically synthesized peptide drug, not a biologic |
Tirzepatide does not face conventional biosimilar risk because it is regulated as a drug rather than a biologic under the biosimilar pathway. The relevant competitor pathway is an abbreviated new drug application, although peptide characterization, manufacturing controls, device compatibility, and clinical bridging can make development more complex than a typical tablet generic.
How strong is the tirzepatide patent estate?
The estate is commercially strong because:
- The core composition patent extends into 2036.
- Lilly controls the reference products and manufacturing process.
- Tirzepatide is a complex peptide requiring high-quality sterile production.
- The products use proprietary delivery presentations.
- Demand is large enough to justify aggressive patent enforcement.
- Formulation, device, and method-of-use patents can create additional litigation layers.
The estate is not invulnerable. Composition patents can face enablement, written-description, obviousness, and claim-construction challenges. A challenger may also design around formulation or delivery patents. The commercial strength of the estate will depend on claim scope, prosecution history, validity evidence, and the exact patents listed for each product.
What is the status of compounded tirzepatide?
Compounded tirzepatide became a major competitive issue during periods when FDA recognized tirzepatide as being in shortage. Compounding pharmacies and telehealth companies used the shortage framework to supply products that competed with Mounjaro and Zepbound at lower prices.
In February 2025, FDA determined that the tirzepatide shortage had been resolved. The agency subsequently addressed the transition period for compounders operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.[9]
The end of the shortage designation reduces the legal basis for routine large-scale compounding, but it does not immediately eliminate all compounded supply. Enforcement timing, state pharmacy rules, patient-specific prescriptions, litigation, and FDA policy can affect the market.
Compounded products create three distinct risks for Lilly:
- Price competition for cash-pay patients.
- Diversion of demand from branded pens during supply constraints.
- Potential quality and pharmacovigilance concerns that affect the broader tirzepatide category.
They also create a regulatory opportunity for Lilly by improving the relative value of FDA-approved products with standardized dose, labeling, quality controls, and manufacturer support.
What licensing deals affect tirzepatide?
Eli Lilly is the principal commercial owner of tirzepatide. No major third-party commercial license has displaced Lilly’s control of the active ingredient or branded products.
The relevant external relationships are more likely to involve:
- Contract manufacturing.
- Injectable-device suppliers.
- Fill-finish capacity.
- Regional distribution.
- Clinical research.
- Technology agreements supporting peptide manufacturing.
Lilly’s manufacturing investments include large-scale facilities in the United States and Europe. The company has committed substantial capital to increasing incretin production, including investments associated with its Lebanon, Indiana manufacturing site and other facilities.[10]
Manufacturing agreements can create practical barriers even where patents are challenged. A competitor must produce a consistent peptide, meet sterile manufacturing requirements, obtain FDA approval, and supply an injection device at commercial scale.
What manufacturing barriers affect tirzepatide competition?
Tirzepatide production requires:
- Peptide synthesis and purification.
- Control of impurities and aggregation.
- Sterile fill-finish operations.
- Stability data across the labeled storage period.
- Validated analytical methods.
- Reliable injection-device supply.
- Cold-chain and distribution controls.
A generic applicant may be able to demonstrate pharmaceutical equivalence without reproducing Lilly’s manufacturing process. In practice, however, scale, yield, impurity control, and device integration can delay launch and increase development costs.
Manufacturing capacity is also a revenue driver for Lilly. Every additional production line can convert unmet prescription demand into reported sales, provided payer access and patient persistence remain strong.
What litigation and settlement risks affect tirzepatide?
The principal litigation categories are:
- Paragraph IV patent litigation against ANDA applicants.
- Patent suits against compounders or telehealth distributors.
- Trade-secret or contract disputes involving manufacturing partners.
- Product-liability claims related to adverse events.
- Advertising and promotional disputes.
- Patent challenges involving formulations, devices, or indications.
A future settlement could include a negotiated generic launch date, a license, supply terms, a first-to-market arrangement, or restrictions on the competing product’s label. Settlement economics would depend on the strength of the core patent, the challenger’s exclusivity position, the expected litigation timeline, and the value of preserving premium pricing.
How does tirzepatide affect Eli Lilly’s valuation and revenue exposure?
Tirzepatide is now a concentration risk as well as a growth engine. Approximately $16.5 billion of 2024 revenue came from Mounjaro and Zepbound. Any adverse event affecting safety perception, reimbursement, manufacturing, or patent validity could have an outsized effect on Lilly’s revenue trajectory.
The principal valuation supports are:
- Large diabetes and obesity patient populations.
- Higher efficacy than several competing incretin products.
- New indications, including obstructive sleep apnea.
- International expansion.
- Higher production capacity.
- Potential use in cardiovascular, metabolic, and liver-related conditions under investigation.
The principal valuation risks are:
- Reimbursement contraction.
- Net-price erosion.
- Reduced patient persistence.
- Competition from semaglutide and next-generation incretins.
- Oral therapy substitution.
- Regulatory restrictions on obesity-drug coverage.
- Earlier-than-expected generic or licensed entry.
Key Takeaways
- Mounjaro and Zepbound generated approximately $16.5 billion in combined revenue in 2024.
- Tirzepatide is Eli Lilly’s primary growth franchise and represented roughly 37% of 2024 company revenue.
- Zepbound’s obesity and obstructive sleep apnea approvals materially expand the addressable market.
- The core U.S. composition patent, U.S. Patent No. 10,034,938, is reported to expire in July 2036, subject to applicable adjustments.
- FDA regulatory exclusivity is expected to expire before the core patent, making patent litigation the central generic-entry issue.
- Tirzepatide faces generic-drug risk, not biosimilar risk.
- Compounded tirzepatide created major cash-pay competition during the FDA shortage period, but FDA’s February 2025 shortage resolution changes the legal framework for routine compounding.
- Manufacturing scale, sterile fill-finish capacity, payer coverage, and patient persistence will determine revenue growth before patent expiry.
- Lilly’s largest commercial risk is concentration in a rapidly growing but increasingly competitive incretin market.
FAQs
Can tirzepatide be sold as a generic before 2036?
A generic could launch before 2036 only if it successfully challenges relevant patents, obtains a license, or markets a product that does not infringe enforceable claims. The core composition patent is the principal barrier.
Will Zepbound and Mounjaro have separate patent expiration dates?
They may have different listed patents and indication-specific protections even though both contain tirzepatide. The core active-ingredient patent can apply broadly, while formulation, method-of-use, and device patents may differ by product.
Is tirzepatide protected by orphan-drug exclusivity?
Mounjaro and Zepbound are not primarily protected by orphan-drug exclusivity. Their commercial protection comes from patents, FDA regulatory exclusivity, manufacturing control, and brand approvals.
Could an oral tirzepatide product replace Mounjaro or Zepbound?
An oral tirzepatide product could compete with weekly injections if Lilly or another company develops and obtains approval for a commercially practical formulation. Oral delivery would likely expand treatment access but could also increase manufacturing and formulation complexity.
What would happen to tirzepatide prices after generic entry?
Prices would likely decline, but the magnitude would depend on the number of entrants, the availability of interchangeable presentations, payer contracting, device differences, and whether Lilly launches an authorized generic or retains a branded cash-pay segment.
References
- Eli Lilly and Company. (2025). 2024 annual report.
- Eli Lilly and Company. (2025, February 6). Eli Lilly and Company reports fourth-quarter and full-year 2024 results and provides 2025 guidance.
- Eli Lilly and Company. (2025, December 4). Lilly’s SURMOUNT-5 phase 3 trial demonstrates tirzepatide delivered greater weight loss than semaglutide in adults with obesity.
- U.S. Food and Drug Administration. (2024, December 20). FDA approves first medication for obstructive sleep apnea.
- U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,034,938, Peptide compounds.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the new drug application process and exclusivity.
- U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and ANDA patent certifications.
- U.S. Food and Drug Administration. (2025, February 21). FDA clarifies policies for compounders as national GLP-1 supply stabilizes.
- Eli Lilly and Company. (2024, May 24). Lilly announces major investment in U.S. manufacturing to increase active pharmaceutical ingredient production for Zepbound and Mounjaro.
